INDUSTRY STAKEHOLDERS AND RESEARCHERS ARE ACTIVELY COLLABORATING TO EXPANDING THEIR EXISTING INFRAST

In the pharmaceutical industry, stakeholders are known to adopt a variety partnership models. Such initiatives not only allow the companies to expand their respective product / therapy, but also to gain additional capabilities in emerging technologies. In the domain of TIL-based therapies, eleven different types of partnership deals were found to be inked between different stakeholders. These include, acquisition, clinical trial agreement, joint venture, manufacturing agreement, product development agreement, product development and commercialization agreement, product licensing agreement, product supply management agreement, R&D agreement, technology licensing and others.

During our research, we came across several partnership agreements, inked during the period 2005-2020 (till October). The number of partnerships has increased at a CAGR of 53%, between 2014 and 2020. It is important to highlight that maximum number of partnerships were recorded in 2017, 2018 and 2019, followed by 2015 (6). Majority of the deals signed in 2016, were R&D agreements, followed by agreements signed for technology licensing, clinical trial agreements and manufacturing agreements.

Majority (33%) of the agreements were signed for R&D (13) and technology and product licensing (8) of TIL-based products. This is followed by agreements focused on manufacturing (15%), clinical trials and product supply management, which account for 5% each of the total partnerships inked in this domain, respectively. Recent examples include the product licensing agreement signed between Iovance Biotherapeutics and TrakCel in September 2017.
To request for Sample report – https://www.rootsanalysis.com/reports/til-therapies-market/request-sample.html
Funding Initiatives

Leave a Reply